Nine To Noon ADHD drugs shortages expect to continue in 2026
Mar 4, 2026
Dr Michael Buckley, Wellington GP specialising in ADHD, offers a clinical take on treatment and supply headaches. He talks about unpredictable prescriptions and pharmacy substitutions. He explains how differing tablet strengths and release profiles affect timing and behaviour. He outlines rising demand, manufacturing fragility, and risks of sourcing meds overseas.
AI Snips
Chapters
Transcript
Episode notes
Methylphenidate Shortages Drive Treatment Shifts
- Methylphenidate shortages are the most noticeable problem and disrupt usual prescribing patterns.
- Pharmac funded a new methylphenidate brand and lisdexamfetamine, but these differ in release profiles and clinical effect.
Expect Pharmacists To Substitute Strengths But Get New Prescriptions
- Pharmacists can substitute tablet strengths (eg, two 18mg for one 36mg) but prescribers must still issue a matching prescription.
- Michael Buckley says this logistical back-and-forth adds complexity and delays for families and clinics.
Release Profiles Change Daytime Symptom Control
- Different long‑acting preparations have distinct release profiles, so swapping can change when symptom control occurs.
- Buckley warns parents may notice behavioural changes if peak effect timing shifts during the day.